Evidence map›Paper›PMID 26403659›Full record

ArticleNeurotoxicity research2016

CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.

Fabrine Sales Massafera Tristão, Márcio Lazzarini, Sabine Martin, Majid Amar, Walter Stühmer, Frank Kirchhoff, Lucas Araújo Caldi Gomes, Laurance Lanfumey, Rui D Prediger, Julia E Sepulveda and 2 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Neurotoxicity research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Role of Microglia in Psychostimulant Addiction.Current neuropharmacology · 2023
    Review
  8. Microglia as Therapeutic Target for Radiation-Induced Brain Injury.International journal of molecular sciences · 2022
    Review
  9. Article
  10. T cells, α-synuclein and Parkinson disease.Handbook of clinical neurology · 2022
    Review
  11. Review
  12. Review
  13. Genetic Rescue Reverses Microglial Activation in Preclinical Models of Retinitis Pigmentosa.Molecular therapy : the journal of the American Society of Gene Therapy · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 3 countries.

Fabrine Sales Massafera TristãoSorbonne Université UPMC UM75 INSERM U1127, CNRS UMR 7225, Institut du Cerveau et de la Moelle Epinière, Thérapeutique Expérimentale de la neurodégénérescence, Hôpital de la Salpêtrière - Bâtiment ICM, 47 boulevard de l'Hôpital, 75651, Paris, France.
Márcio LazzariniDepartment of Molecular Biology of Neuronal Signals, Max Planck Institute of Experimental Medicine, Göttingen, Germany.
Sabine MartinDepartment of Molecular Biology of Neuronal Signals, Max Planck Institute of Experimental Medicine, Göttingen, Germany.
Majid AmarSorbonne Université UPMC UM75 INSERM U1127, CNRS UMR 7225, Institut du Cerveau et de la Moelle Epinière, Thérapeutique Expérimentale de la neurodégénérescence, Hôpital de la Salpêtrière - Bâtiment ICM, 47 boulevard de l'Hôpital, 75651, Paris, France.
Walter StühmerDepartment of Molecular Biology of Neuronal Signals, Max Planck Institute of Experimental Medicine, Göttingen, Germany.
Frank KirchhoffDepartment of Molecular Physiology, University of Saarland, Homburg, Germany.
Lucas Araújo Caldi GomesDepartment of Molecular Biology of Neuronal Signals, Max Planck Institute of Experimental Medicine, Göttingen, Germany.
Laurance LanfumeyINSERM UMR S894, Université Pierre et Marie Curie, UPMC, Paris, France.
Rui D PredigerDepartamento de Farmacologia, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, UFSC, Campus Trindade, Florianópolis, SC, Brazil.
Julia E SepulvedaSorbonne Université UPMC UM75 INSERM U1127, CNRS UMR 7225, Institut du Cerveau et de la Moelle Epinière, Thérapeutique Expérimentale de la neurodégénérescence, Hôpital de la Salpêtrière - Bâtiment ICM, 47 boulevard de l'Hôpital, 75651, Paris, France.
Elaine A Del-BelDepartment of Morphology, Physiology and Basic Pathology (MFPb-Fisiologia), School of Odontology, University of Sao Paulo (USP), Av Café s/n 14040-220, Ribeirão Preto, SP, Brazil. eadelbel@forp.usp.br.
Rita Raisman-VozariSorbonne Université UPMC UM75 INSERM U1127, CNRS UMR 7225, Institut du Cerveau et de la Moelle Epinière, Thérapeutique Expérimentale de la neurodégénérescence, Hôpital de la Salpêtrière - Bâtiment ICM, 47 boulevard de l'Hôpital, 75651, Paris, France. ritaraisman@gmail.com.
Sorbonne Université · FRInstitut du Cerveau · FRMax Planck Institute of Experimental Medicine · DENanoscale Microscopy and Molecular Physiology of the Brain Cluster of Excellence 171 — DFG Research Center 103 · DESaarland University · DEUniversidade de São Paulo · BRUniversidade Federal de Santa Catarina · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is characterized by progressive degeneration of dopaminergic neurons accompanied by an inflammatory reaction. The neuron-derived chemokine fractalkine (CX3CL1) is an exclusive ligand for the receptor CX3CR1 expressed on microglia. The CX3CL1/CX3CR1 signaling is important for sustaining microglial activity. Using a recently developed PD model, in which the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) toxin is delivered intranasally, we hypothesized that CX3CR1 could play a role in neurotoxicity and glial activation. For this, we used CX3CR1 knock-in mice and compared results with those obtained using the classical PD models through intraperitonal MPTP or intrastriatal 6-hydroxydopamine (6-OHDA). The striatum from all genotypes (CX3CR1(+/+), CX3CR1(+/GFP) and CX3CR1-deficient mice) showed a significant dopaminergic depletion after intranasal MPTP inoculation. In contrast to that, we could not see differences in the number of dopaminergic neurons in the substantia nigra of CX3CR1-deficient animals. Similarly, after 6-OHDA infusion, the CX3CR1 deletion decreased the amphetamine-induced turning behavior observed in CX3CR1(+/GFP) mice. After the 6-OHDA inoculation, a minor dopaminergic neuronal loss was observed in the substantia nigra from CX3CR1-deficient mice. Distinctly, a more extensive neuronal cell loss was observed in the substantia nigra after the intraperitoneal MPTP injection in CX3CR1 disrupted animals, corroborating previous results. Intranasal and intraperitoneal MPTP inoculation induced a similar microgliosis in CX3CR1-deficient mice but a dissimilar change in the astrocyte proliferation in the substantia nigra. Nigral astrocyte proliferation was observed only after intraperitoneal MPTP inoculation. In conclusion, intranasal MPTP and 6-OHDA lesion in CX3CR1-deficient mice yield no nigral dopaminergic neuron loss, linked to the absence of astroglial proliferation.

Indexed as

Administration, IntranasalAnimalsAstrocytesCorpus StriatumCX3C Chemokine Receptor 1DopamineDopaminergic NeuronsEncephalitisGliosisInjections, IntraperitonealMiceMice, TransgenicMicrogliaOxidopamineParkinsonian DisordersReceptors, ChemokineCX3C Chemokine Receptor 1Cx3cr1 protein, mouseDopamineOxidopamineReceptors, Chemokine6-OHDAFractalkine (CX3CL1)Fractalkine receptor (CX3CR1)MPTPNeurodegenerationNeuroinflammationParkinson’s disease

Identifiers

PMID26403659
OpenAlexW2177051077

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.